All In Biotech

Drug Trial Radar · NCT05731050

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Sep 2027

Study completion Mar 2028

Sponsor

Lead sponsor
NovelMed TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.

Conditions

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • NM8074Drug

    NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84. For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study. Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Normalization of serum LDH(Lactate dehydrogenase) levels from baseline levelsTime frame: Up to Week 12
  2. Change from Baseline or Percent Change from Baseline in total hemoglobin levels (g/dL)Time frame: Up to Week 12
  3. Change from Baseline or Percent Change from Baseline in total number of units of packed red blood cells (pRBCs) transfused through Week 12Time frame: Up to Week 12
  4. Change from Baseline or Percent Change from Baseline in number of transfusionsTime frame: Up to Week 12
  5. Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Levels of MAC via Classical Pathway (CP) of Complement ActivityTime frame: Up to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.